Citigroup
ONCY

Citigroup’s Oncolytics Biotech ONCY Stock Holding History

Citigroup’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.8K Buy
+29,223
New +$27.1K ﹤0.01% 5100
2026
Q1 		– Sell
-1
Closed -$1 – 6266
2025
Q4 		$1 Buy
+1
New +$1 ﹤0.01% 5982
2025
Q3 		– Sell
-333
Closed -$254 – 6245
2025
Q2 		$254 Buy
+333
New +$176 ﹤0.01% 5469
2018
Q3 		– Sell
-947
Closed -$5K – 7832
2018
Q2 		$5K Buy
+947
New +$5.83K ﹤0.01% 7352

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.71B AUM 30.33% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PAS
Professional Advisory Services Vero Beach, Florida $836M AUM 25.79% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Citigroup's ONCY Position: Q2 2026 in Review

Citigroup opened a new position in Oncolytics Biotech (ONCY) in Q2 2026: 29,223 shares worth $27.8K. The stake represents ﹤0.01% of the portfolio and ranks #5100 among its holdings. This is a return to the name: Citigroup previously reported a position in ONCY as recently as Q4 2025.

Citigroup first reported a position in ONCY in Q2 2018 and has held it in 4 quarters since. 24 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • Citigroup held 29,223 shares of Oncolytics Biotech worth $27.8K as of Q2 2026.
  • Oncolytics Biotech was a new Citigroup position in Q2 2026.
  • Oncolytics Biotech made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5100 holding.
  • Citigroup first reported a position in Oncolytics Biotech in Q2 2018 and has held it in 4 quarters since.
  • 24 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.